Physician
Atmed Treatment Center, INC.
Atmed Treatment Center, INC. was paid $3.13M by Medicaid between Jan 2018 and Dec 2024, across 32 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoATMED TREATMENT CENTER, INC.
JOHNSTON, RI 02919
JOHNSTON, RI 02919
33aNPI1558490151assigned 03/02/2007
33bProvider typeInternal Medicine Physician
28Total paid$3.13M
24GClaims69,957
24DCodes billed32
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Rhode Island
Rank by total paid#4 of 386
Median peer was paid$15K
This provider vs. median204×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,140 | $442K | |
| 2019 | 13,835 | $636K | |
| 2020 | 8,252 | $350K | |
| 2021 | 9,598 | $432K | |
| 2022 | 9,122 | $447K | |
| 2023 | 8,391 | $372K | |
| 2024incomplete | 10,619 | $454K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 18,370 | 16,741 | $864K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27% | 12,039 | 11,275 | $847K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 4,651 | 4,417 | $341K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 10% | 11,490 | 10,854 | $316K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 8.0% | 2,430 | 2,339 | $250K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 6.4% | 3,229 | 3,073 | $199K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.1% | 4,313 | 4,180 | $128K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.1% | 3,948 | 3,578 | $66K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 3,270 | 1,579 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,476 | 1,394 | $25K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 47 | 47 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 754 | 724 | $7K |
20 more codes
| 0002A | <1% | 181 | $7K | |
| 0001A | <1% | 134 | $5K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 16 | $4K |
| 81002 | <1% | 1,676 | $4K | |
| 0003A | <1% | 94 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 29 | $3K |
| 81000 | <1% | 1,013 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 350 | $2K |
| 72100 | <1% | 90 | $2K | |
| 70210 | <1% | 73 | $1K | |
| 72040 | <1% | 44 | $874.99 | |
| 73610 | <1% | 50 | $847.52 | |
| 73630 | <1% | 42 | $680.41 | |
| 87428 | <1% | 13 | $650.00 | |
| 0011A | <1% | 13 | $541.24 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 14 | $497.00 |
| 0012A | <1% | 12 | $457.93 | |
| 99000 | <1% | 67 | $197.65 | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 16 | $0.16 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREGAN, DANIEL (MEDICAL DIRECTOR)